The development of AZD7624 for prevention of exacerbations in COPD: A randomized controlled trial

Naimish R. Patel, Danen M. Cunoosamy, Malin Fagerås, Ziad Taib, Sara Asimus, Tove Hegelund-Myrbäck, Sofia Lundin, Katerina Pardali, Nisha Kurian, Eva Ersdal, Cecilia Kristensson, Katarina Korsback, Robert Palmér, Mary N. Brown, Steven Greenaway, Leonard Siew, Graham W. Clarke, Stephen I. Rennard, Barry J. Make, Robert A. WisePaul Jansson

Research output: Contribution to journalArticle

Abstract

Background: p38 mitogen-activated protein kinase (MAPK) plays a central role in the regulation and activation of pro-inflammatory mediators. COPD patients have increased levels of activated p38 MAPK, which correlate with increased lung function impairment, alveolar wall inflammation, and COPD exacerbations. Objectives: These studies aimed to assess the effect of p38 inhibition with AZD7624 in healthy volunteers and patients with COPD. The principal hypothesis was that decreasing lung inflammation via inhibition of p38α would reduce exacerbations and improve quality of life for COPD patients at high risk for acute exacerbations. Methods: The p38 isoform most relevant to lung inflammation was assessed using an in situ proximity ligation assay in severe COPD patients and donor controls. Volunteers aged 18–55 years were randomized into the lipopolysaccharide (LPS) challenge study, which investigated the effect of a single dose of AZD7624 vs placebo on inflammatory biomarkers. The Proof of Principle study randomized patients aged 40–85 years with a diagnosis of COPD for >1 year to AZD7624 or placebo to assess the effect of p38 inhibition in decreasing the rate of exacerbations. Results: The p38 isoform most relevant to lung inflammation was p38α, and AZD7624 specifically inhibited p38α and p38β isoforms in human alveolar macrophages. Thirty volunteers were randomized in the LPS challenge study. AZD7624 reduced the increase from baseline in sputum neutrophils and TNF-α by 56.6% and 85.4%, respectively (p<0.001). In the 213 patients randomized into the Proof of Principle study, there was no statistically significant difference between AZD7624 and placebo when comparing the number of days to the first moderate or severe exacerbation or early dropout. Conclusion: Although p38α is upregulated in the lungs of COPD patients, AZD7624, an isoform-specific inhaled p38 MAPK inhibitor, failed to show any benefit in patients with COPD.

Original languageEnglish (US)
Pages (from-to)1009-1019
Number of pages11
JournalInternational Journal of COPD
Volume13
DOIs
StatePublished - Mar 27 2018

Keywords

  • COPD
  • Inflammation
  • P38 mitogen-activated protein kinase

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'The development of AZD7624 for prevention of exacerbations in COPD: A randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Patel, N. R., Cunoosamy, D. M., Fagerås, M., Taib, Z., Asimus, S., Hegelund-Myrbäck, T., Lundin, S., Pardali, K., Kurian, N., Ersdal, E., Kristensson, C., Korsback, K., Palmér, R., Brown, M. N., Greenaway, S., Siew, L., Clarke, G. W., Rennard, S. I., Make, B. J., ... Jansson, P. (2018). The development of AZD7624 for prevention of exacerbations in COPD: A randomized controlled trial. International Journal of COPD, 13, 1009-1019. https://doi.org/10.2147/COPD.S150576